Skip to main content

Published locations for FDA panel says benefits of necitumumab for squamous NSCLC outweigh risks

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA panel says benefits of necitumumab for squamous NSCLC outweigh risks

User login

  • Reset your password
  • /content/fda-panel-says-benefits-necitumumab-squamous-nsclc-outweigh-risks
  • /oncologypractice/article/101166/lung-cancer/fda-panel-says-benefits-necitumumab-squamous-nsclc
  • /node/155702/article/101166/lung-cancer/fda-panel-says-benefits-necitumumab-squamous-nsclc-outweigh
  • /hematology-oncology/article/101166/lung-cancer/fda-panel-says-benefits-necitumumab-squamous-nsclc
  • /chestphysician/article/101166/lung-cancer/fda-panel-says-benefits-necitumumab-squamous-nsclc